MOH Announces Extended Subsidies and MediSave Use for Shingles Vaccination

In a significant move to enhance public health, the Ministry of Health (MOH) in Singapore has announced the extension of subsidies for the shingles vaccine, Shingrix, starting in September 2025. Additionally, from 2026, individuals can utilize their MediSave accounts to cover the remaining costs of the vaccine after subsidies. 

This initiative aims to make shingles vaccination more accessible and affordable, particularly for seniors who are at higher risk of developing shingles and its associated complications. The decision to extend financial support for the vaccine reflects the government’s commitment to preventive healthcare and reducing the burden of infectious diseases in an aging population.

Understanding Shingles and Its Impact

Shingles, medically known as herpes zoster, is a painful rash illness caused by the reactivation of the varicella-zoster virus—the same virus responsible for chickenpox. After an individual recovers from chickenpox, the virus remains dormant in the nerve tissues and can reactivate years later, leading to shingles.

The condition is characterized by a painful rash, often accompanied by blisters, which typically appear on one side of the body. In some cases, the pain and discomfort persist even after the rash heals, leading to a severe condition known as postherpetic neuralgia (PHN). This long-term nerve pain can last for months or even years, significantly affecting the quality of life.

The risk of developing shingles increases with age, particularly in individuals over 50, as the immune system weakens with time. Other risk factors include chronic medical conditions, stress, and immunosuppressive treatments such as chemotherapy. Given the debilitating nature of shingles and the potential for long-term complications, vaccination is a crucial preventive measure.

Details of the Subsidy and MediSave Scheme

From September 2025, eligible Singaporeans and Permanent Residents (PRs) can receive means-tested subsidies of up to 75% for the Shingrix vaccine at Community Health Assist Scheme (CHAS) General Practitioner (GP) clinics, polyclinics, and MOH-funded long-term care institutions.

After applying these subsidies, Singaporeans can expect to pay approximately S$75 to S$300 per course of the shingles vaccine, while PRs will pay around S$450 per course. The price varies based on the individual’s income level and eligibility for CHAS benefits. For those who still find the costs challenging, the government has taken an additional step by allowing the use of MediSave to cover any remaining out-of-pocket expenses starting in 2026.

This means that, depending on their MediSave balance, eligible individuals may not need to pay anything out of pocket for shingles vaccination. This initiative particularly benefits older adults, who are at the highest risk of developing severe shingles complications but may be hesitant due to financial constraints.

Rationale Behind the Initiative

The decision to extend subsidies and MediSave usage for the Shingrix vaccine stems from a recognition of its importance in preventing shingles, especially among the aging population. Previously, the high cost of the vaccine—often exceeding S$500 per course—posed a barrier for many individuals who wanted to protect themselves but found it financially unfeasible. The MOH’s move to subsidize the vaccine aims to address these concerns and encourage more people to take preventive measures.

By making the shingles vaccination more affordable, the government hopes to reduce the overall healthcare burden associated with treating shingles and its complications. Hospitalizations due to severe shingles cases, particularly in older individuals, can be costly and may lead to prolonged recovery periods. Additionally, individuals suffering from postherpetic neuralgia often require long-term pain management, adding to healthcare costs.

Encouraging vaccination through financial support is part of a broader public health strategy to promote preventive care. The success of previous vaccination programs—such as the pneumococcal and influenza vaccination subsidies—has demonstrated that making vaccines more accessible leads to higher uptake and better public health outcomes.

Who Should Get the Shingles Vaccination?

The shingles vaccine is recommended for individuals aged 50 and older, even if they have previously had shingles. Those with weakened immune systems, such as individuals undergoing cancer treatments, organ transplant recipients, and those with chronic conditions like diabetes, may also benefit from the vaccine.

Shingrix is a non-live vaccine, which means it is safe for people with weakened immune systems, unlike the older Zostavax vaccine, which contained a live virus. It is administered in two doses, given two to six months apart, and provides strong protection against shingles and postherpetic neuralgia.

How to Access the Subsidized Vaccination

Eligible individuals interested in receiving the subsidized shingles vaccination can do so at participating CHAS GP clinics, polyclinics, and MOH-funded long-term care institutions starting in September 2025. It is advisable to consult with a healthcare provider to discuss the suitability of the vaccine based on individual health conditions.

Healthcare providers will also be able to guide individuals through the subsidy application process and explain how MediSave funds can be used to cover the cost of the vaccine. Booking an appointment in advance is recommended, as demand for the vaccine is expected to rise following the announcement of these financial incentives.

Addressing Common Concerns About the Vaccine

Despite the clear benefits of shingles vaccination, some individuals may hesitate due to concerns about side effects. Like any vaccine, Shingrix may cause mild side effects, such as soreness at the injection site, fatigue, headache, or mild fever. These symptoms typically resolve within a few days. Severe side effects are rare, and the benefits of protection against shingles far outweigh the potential temporary discomfort.

Another common concern is whether individuals who have already had shingles should still get vaccinated. The answer is yes—having had shingles does not provide lifelong immunity, and reinfection can occur. Experts recommend waiting at least a year after a shingles episode before getting vaccinated to allow the immune system to recover.

The Bigger Picture: Preventive Healthcare in Singapore

The expansion of subsidies and MediSave use for shingles vaccination aligns with Singapore’s broader strategy of promoting preventive healthcare. By focusing on vaccination and early disease prevention, the government aims to reduce the strain on the healthcare system, lower long-term medical costs, and improve the overall well-being of its citizens.

Preventive healthcare measures, including routine vaccinations, regular health screenings, and chronic disease management, play a critical role in ensuring that Singapore’s population remains healthy and that the healthcare system remains sustainable. Encouraging people to take proactive steps in protecting their health can lead to a healthier aging population and fewer hospital admissions due to preventable diseases.

Conclusion

The MOH’s initiative to extend subsidies and MediSave usage for the Shingrix vaccine marks a significant step forward in preventive healthcare for Singapore’s aging population. By making shingles vaccination more affordable and accessible, the government aims to reduce the prevalence of this painful condition and its complications, ultimately enhancing the well-being of its citizens.

Eligible individuals should take advantage of this opportunity by scheduling their shingles vaccination at CHAS GP clinics, polyclinics, or MOH-funded institutions once the subsidy program launches. With financial barriers removed, there is no reason to delay protecting oneself against shingles. Investing in preventive healthcare today can lead to a healthier and more comfortable future for individuals and the healthcare system alike.